THERMO FISHER SCIENTIFIC INC.
No enriched coverage for $TMO in the last 7 days.
UBS expects Thermo Fisher (TMO) to achieve 5-6% organic growth and 50-70 basis points of margin expansion, leading to double-digit EPS growth. Danaher (DHR) may return to mid-single-digit growth next year, potentially regaining its valuation premium over peers. Both companies could see improved performance due to operating leverage.
UBS upgraded Thermo Fisher Scientific (TMO) to Buy with a $730 price target. Wells Fargo downgraded Vulcan Materials (VMC) to Underweight with a $254 target. Other upgrades and downgrades were announced by various firms.
Analysts made several rating changes: TD Cowen initiated Faeth Therapeutics as buy, Barclays upgraded Sagimet Biosciences to overweight, JPMorgan upgraded Lithium Americas to overweight, and more. Price targets were also adjusted for companies like Affirm, Robinhood, and First Solar.
Recent TMO coverage spans financial news, technology and sector analysis.
In the last 30 days, TMO insiders filed 21 SEC Form 4 transactions — no purchases and 21 sales ($22.3M). The most active reporter was CASPER MARC N, Chairman & CEO, with 18 filings. 95% of those filings were made under pre-arranged Rule 10b5-1 plans.
Potential margin lift could boost earnings and support the stock.
Potential upside as analysts raise outlook.
Upgrade may reinforce bullish sentiment.
The launch may boost demand for Thermo Fisher's microscopy portfolio, especially among semiconductor and materials research labs planning upgrades.
Potential upside.
AlphAI scores every news story that mentions TMO with an AI model for sentiment and relevance, and aggregates insider trades from THERMO FISHER SCIENTIFIC INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS expects Thermo Fisher (TMO) to achieve 5-6% organic growth and 50-70 basis points of margin expansion, leading to double-digit EPS growth. Danaher (DHR) may return to mid-single-digit growth next year, potentially regaining its valuation premium over peers. Both companies could see improved performance due to operating leverage.
2 min readUBS upgraded Thermo Fisher Scientific (TMO) to Buy with a $730 price target. Wells Fargo downgraded Vulcan Materials (VMC) to Underweight with a $254 target. Other upgrades and downgrades were announced by various firms.
2 min readAnalysts made several rating changes: TD Cowen initiated Faeth Therapeutics as buy, Barclays upgraded Sagimet Biosciences to overweight, JPMorgan upgraded Lithium Americas to overweight, and more. Price targets were also adjusted for companies like Affirm, Robinhood, and First Solar.
3 min readThermo Fisher Scientific launched the EMPAD G2, a 4D STEM detector with 10,000 fps speed and dynamic range exceeding 10⁷. It enables simultaneous structural, chemical, and field data capture, addressing high-throughput research needs. The company aims to accelerate discoveries in semiconductors, energy, and advanced materials.
2 min readAnalysts upgraded Broadcom (AVGO) to Outperform with a $490 target, Deere (DE) to Outperform with an $813 target, and Dell (DELL) to Outperform with a $625 target. Moderna (MRNA) was downgraded to Sell with an $81 target. Seaport Research initiated Buy ratings on Devon Energy (DVN), Permian Resources (PR), and Viper Energy (VNOM).
3 min readModerna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.
3 min readPettiti Gianluca (President & COO) sold 4,133 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $614.38 ($2.54M total) across 2 trades on 2026-08-31 under a Rule 10b5-1 trading plan.
1 min readThermo Fisher Scientific (TMO) launched the EMPAD G2 detector for advanced materials analysis, aiming to boost its Analytical Instruments segment. Shares dipped 0.8% post-announcement. The company has a $233.20B market cap, 4% earnings yield, and a track record of beating earnings estimates. The global 4D STEM market, where EMPAD G2 operates, is projected to grow at 6.6% CAGR through 2031, according to QYResearch.
3 min readHSBC raised its price target for Thermo Fisher Scientific to $690 from $660, maintaining a buy rating. The stock is currently trading at $602.29, down 2.40% on the day and 4.23% over the past year. The company recently introduced a new electron detector.
1 min readBio-Techne (TECH) reported flat earnings, trading at $72.35. Avantor (AVTR) beat estimates with $1.69B revenue, up 17.4%. Bruker (BRKR) missed expectations, down 11.1%. Sotera Health (SHC) reported $321.4M revenue, up 7.2%. Thermo Fisher (TMO) beat estimates with $11.99B revenue, up 18.3%.
3 min read
